Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus

被引:0
|
作者
Munoz-Torres, M. [1 ,2 ,3 ]
Carazo-Gallego, A. [4 ]
Jimenez-Lopez, J. C. [5 ,6 ,7 ]
Aviles-Perez, M. D. [2 ,3 ]
Diaz-Arco, S. [8 ]
Lozano-Alonso, S. [9 ]
Lima-Cabello, E. [5 ]
Alche, J. de Dios [5 ]
Reyes-Garcia, R. [3 ,10 ]
Morales-Santana, S. [3 ,11 ]
机构
[1] Univ Granada, Fac Med, Dept Med, Granada, Spain
[2] Hosp Univ San Cecilio, Inst Invest Biosanitaria Granada IbsGRANADA, UGC Endocrinol & Nutr, Unidad Metabolismo Oseo, Granada, Spain
[3] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER, Area Temat CIBER Fragilidad & Envejecimiento Salu, Madrid, Spain
[4] Hosp Univ San Cecilio, Inst Biosanitario Granada, Unidad Enfermedades Digest, Granada, Spain
[5] CSIC, Estn Expt Zaidin, Dept Bioquim Biol Celular & Mol Plantas, Granada, Spain
[6] Univ Oeste Australia UWA, Inst Agr, Perth, WA, Australia
[7] Univ Oeste Australia UWA, Escuela Agr & Medioambiente, Perth, WA, Australia
[8] Univ Granada, Hosp Univ San Cecilio, Inst Invest Biosanitaria Granada IbsGRANADA, Granada, Spain
[9] Hosp Univ San Cecilio, Serv Angiol & Cirugia Vasc, Granada, Spain
[10] Hosp Univ Torrecardenas, Unidad Endocrinol & Nutr, Almeria, Spain
[11] Hosp Univ San Cecilio, Serv Invest Proteom, Inst Invest Biosanitaria Granada IbsGranada, Granada, Spain
关键词
BONE-MINERAL DENSITY; FRACTURE RISK; CYTOKINES; WOMEN; INTERLEUKIN-10; MARKERS; INSULIN; ALPHA; OLDER; IL-12;
D O I
10.4321/S1889-836X2022000100004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objetive: Type 2 diabetes mellitus (DM2) and osteoporosis are diseases associated with a pro‐inflammatory environment, the prevention of which through new therapeutic strategies could prevent their development. However, there are few studies that evaluate the inflammatory profile of osteoporosis in patients with DM2. This study focuses on evaluating the inflammatory immune response through serum concentrations of nine cytokines, two of them anti‐inflammatory (IL‐10, IL‐5) and six pro‐inflammatory (IL‐2, IL‐6, IL‐12 (p70), IL‐17A, TNFα and IFNγ) in 163 individuals with DM2 and 47 controls. A subpopulation, made up of 43 DM2 patients without osteoporosis, and 33 with osteoporosis, was analyzed in greater depth at the level of bone parameters. Furthermore, we have assessed the calciotropic hormones, bone remodeling markers, bone mineral density and vertebral fractures in the population, and we have analyzed the relationship of the cytokines tested with DM2, osteoporosis and prevalent vertebral fractures. Patients with DM2 had significantly higher serum concentrations of IL‐10 compared to the control group (0.5±1 vs. 0.14±0.3 pg/ml; p=0.016) and the levels of IL12 p70 were shown lower in patients with DM2 compared to controls (2.9±1.6 vs. 3.9±3.1 pg/ml; p=0.027). In the group of patients with DM2 and osteoporosis, the levels of the cytokine IL‐6 were elevated compared to the group with DM2 without osteoporosis (10.9±14.6 vs. 4.5±7.0; p=0.017). An association of IL‐5 was also observed, with its lowest levels in the DM2 group with osteoporosis (1.7±0.2 vs. 3.8±0.6; p=0.032). Furthermore, IL‐5 showed a direct correlation with the levels of the bone formation biomarker alkaline bone phosphatase (r=0.277, p=0.004) in the subpopulation of patients with DM2. The rest of cytokines did not show significant differences. In conclusion, our findings indicate that in our study population, patients with DM2 compared to healthy subjects present an inflammatory profile opposite to what is expected in a hyperglycemic situation, probably as a compensatory response to the inflammation caused. The cytokine profile is modified in the subpopulation of diabetic patients, depending on the presence of osteoporosis. In this case, the inflammatory profile in the presence of osteoporosis is consistent with the expected response. © 2022 Sociedad Espanola de Investigacion Osea y del Metabolismo Mineral (SEIOMM). All rights reserved.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 50 条
  • [21] THE RELATIONSHIP BETWEEN TYPE 2 DIABETES MELLITUS AND OSTEOPOROSIS IN ELDERLY PATIENTS: A RETROSPECTIVE STUDY
    Abd Elaziz, S.
    Alshaali, A.
    Hammam, M.
    Sobhy, M.
    Aljaziri, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S112 - S112
  • [22] Type 2 diabetes mellitus severity correlates with risk of hip fracture in patients with osteoporosis
    Hsu, J-Y.
    Cheng, C-Y.
    Hsu, C-Y.
    NETHERLANDS JOURNAL OF MEDICINE, 2018, 76 (02): : 65 - 71
  • [23] EARLY DETECTION OF OSTEOPOROSIS IN WOMEN WITH DIABETES MELLITUS TYPE 2
    Bodea, A.
    Birsan, S. D.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S277 - S277
  • [24] Diagnostic relevance of inflammatory markers in female patients with type 2 diabetes mellitus
    Malenica, M.
    Silar, M.
    Dujic, T.
    Bego, T.
    Semiz, S.
    Prnjavorac, B.
    Causevic, A.
    FEBS JOURNAL, 2016, 283 : 243 - 244
  • [25] Anti-inflammatory effects of rosiglitazone in type 2 diabetes mellitus patients
    van Doorn, MBA
    Kemme, M
    Ouwens, M
    van Hoogdalem, EJ
    Liu, X
    Li, QS
    de Kam, ML
    Burggraaf, J
    Cohen, AF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (06) : 680 - 680
  • [26] The anti-inflammatory effects of rosiglitazone in patients with type 2 diabetes mellitus
    Kadoglou, N. P.
    Iliadis, F.
    Liapis, C. D.
    Perrea, D.
    Didangelos, I. P.
    Tsanikidis, H.
    Alevizos, M.
    DIABETOLOGIA, 2007, 50 : S260 - S260
  • [27] Stress, inflammatory markers and factors associated in patients with type 2 diabetes mellitus
    Aguilar-Zavala, Herlinda
    Garay-Sevilla, Ma. Eugenia
    Malacara, Juan Manuel
    Perez-Luque, Elva Leticia
    STRESS AND HEALTH, 2008, 24 (01) : 49 - 54
  • [28] Effects of Rivoglitazone on Metabolic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus
    Truitt, Kenneth E.
    Moberly, James
    Schwocho, Lee
    Mun, Yong
    Chou, Hubert S.
    DIABETES, 2010, 59 : A182 - A182
  • [29] Plasma concentration of inflammatory markers and adiponectin in patients with type 2 diabetes mellitus
    Zurawska-Klis, M
    Drzewoski, J
    DIABETES, 2005, 54 : A544 - A545
  • [30] Effects of Umami Stimulation on Oral Environment of Type 2 Diabetes Mellitus Patients
    Sakai, Chieko
    Horikoshi, Yosuke
    Mizuta, Einosuke
    Matsura, Tatsuya
    Hanaki, Keiichi
    DIABETES, 2024, 73